Cargando…

Pneumococcal Antibody Concentrations and Carriage of Pneumococci more than 3 Years after Infant Immunization with a Pneumococcal Conjugate Vaccine

BACKGROUND: A 9-valent pneumococcal conjugate vaccine (PCV-9), given in a 3-dose schedule, protected Gambian children against pneumococcal disease and reduced nasopharyngeal carriage of pneumococci of vaccine serotypes. We have studied the effect of a booster or delayed primary dose of 7-valent conj...

Descripción completa

Detalles Bibliográficos
Autores principales: Akinsola, Adebayo K., Ota, Martin O. C., Enwere, Godwin C., Okoko, Brown J., Zaman, Syed M. A., Saaka, Mark, Nsekpong, Ekpedeme D., Odutola, Aderonke A., Greenwood, Brian M., Cutts, Felicity T., Adegbola, Richard A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3282700/
https://www.ncbi.nlm.nih.gov/pubmed/22363544
http://dx.doi.org/10.1371/journal.pone.0031050
_version_ 1782224106315317248
author Akinsola, Adebayo K.
Ota, Martin O. C.
Enwere, Godwin C.
Okoko, Brown J.
Zaman, Syed M. A.
Saaka, Mark
Nsekpong, Ekpedeme D.
Odutola, Aderonke A.
Greenwood, Brian M.
Cutts, Felicity T.
Adegbola, Richard A.
author_facet Akinsola, Adebayo K.
Ota, Martin O. C.
Enwere, Godwin C.
Okoko, Brown J.
Zaman, Syed M. A.
Saaka, Mark
Nsekpong, Ekpedeme D.
Odutola, Aderonke A.
Greenwood, Brian M.
Cutts, Felicity T.
Adegbola, Richard A.
author_sort Akinsola, Adebayo K.
collection PubMed
description BACKGROUND: A 9-valent pneumococcal conjugate vaccine (PCV-9), given in a 3-dose schedule, protected Gambian children against pneumococcal disease and reduced nasopharyngeal carriage of pneumococci of vaccine serotypes. We have studied the effect of a booster or delayed primary dose of 7-valent conjugate vaccine (PCV-7) on antibody and nasopharyngeal carriage of pneumococci 3–4 years after primary vaccination. METHODOLOGY/PRINCIPAL FINDINGS: We recruited a subsample of children who had received 3 doses of either PCV-9 or placebo (controls) into this follow-up study. Pre- and post- PCV-7 pneumococcal antibody concentrations to the 9 serotypes in PCV-9 and nasopharyngeal carriage of pneumococci were determined before and at intervals up to 18 months post-PCV-7. We enrolled 282 children at a median age of 45 months (range, 38–52 months); 138 had received 3 doses of PCV-9 in infancy and 144 were controls. Before receiving PCV-7, a high proportion of children had antibody concentrations >0.35 µg/mL to most of the serotypes in PCV-9 (average of 75% in the PCV-9 and 66% in the control group respectively). The geometric mean antibody concentrations in the vaccinated group were significantly higher compared to controls for serotypes 6B, 14, and 23F. Antibody concentrations were significantly increased to serotypes in the PCV-7 vaccine both 6–8 weeks and 16–18 months after PCV-7. Antibodies to serotypes 6B, 9V and 23F were higher in the PCV-9 group than in the control group 6–8 weeks after PCV-7, but only the 6B difference was sustained at 16–18 months. There was no significant difference in nasopharyngeal carriage between the two groups. CONCLUSIONS/SIGNIFICANCE: Pneumococcal antibody concentrations in Gambian children were high 34–48 months after a 3-dose primary infant vaccination series of PCV-9 for serotypes other than serotypes 1 and 18C, and were significantly higher than in control children for 3 of the 9 serotypes. Antibody concentrations increased after PCV-7 and remained raised for at least 18 months.
format Online
Article
Text
id pubmed-3282700
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-32827002012-02-23 Pneumococcal Antibody Concentrations and Carriage of Pneumococci more than 3 Years after Infant Immunization with a Pneumococcal Conjugate Vaccine Akinsola, Adebayo K. Ota, Martin O. C. Enwere, Godwin C. Okoko, Brown J. Zaman, Syed M. A. Saaka, Mark Nsekpong, Ekpedeme D. Odutola, Aderonke A. Greenwood, Brian M. Cutts, Felicity T. Adegbola, Richard A. PLoS One Research Article BACKGROUND: A 9-valent pneumococcal conjugate vaccine (PCV-9), given in a 3-dose schedule, protected Gambian children against pneumococcal disease and reduced nasopharyngeal carriage of pneumococci of vaccine serotypes. We have studied the effect of a booster or delayed primary dose of 7-valent conjugate vaccine (PCV-7) on antibody and nasopharyngeal carriage of pneumococci 3–4 years after primary vaccination. METHODOLOGY/PRINCIPAL FINDINGS: We recruited a subsample of children who had received 3 doses of either PCV-9 or placebo (controls) into this follow-up study. Pre- and post- PCV-7 pneumococcal antibody concentrations to the 9 serotypes in PCV-9 and nasopharyngeal carriage of pneumococci were determined before and at intervals up to 18 months post-PCV-7. We enrolled 282 children at a median age of 45 months (range, 38–52 months); 138 had received 3 doses of PCV-9 in infancy and 144 were controls. Before receiving PCV-7, a high proportion of children had antibody concentrations >0.35 µg/mL to most of the serotypes in PCV-9 (average of 75% in the PCV-9 and 66% in the control group respectively). The geometric mean antibody concentrations in the vaccinated group were significantly higher compared to controls for serotypes 6B, 14, and 23F. Antibody concentrations were significantly increased to serotypes in the PCV-7 vaccine both 6–8 weeks and 16–18 months after PCV-7. Antibodies to serotypes 6B, 9V and 23F were higher in the PCV-9 group than in the control group 6–8 weeks after PCV-7, but only the 6B difference was sustained at 16–18 months. There was no significant difference in nasopharyngeal carriage between the two groups. CONCLUSIONS/SIGNIFICANCE: Pneumococcal antibody concentrations in Gambian children were high 34–48 months after a 3-dose primary infant vaccination series of PCV-9 for serotypes other than serotypes 1 and 18C, and were significantly higher than in control children for 3 of the 9 serotypes. Antibody concentrations increased after PCV-7 and remained raised for at least 18 months. Public Library of Science 2012-02-20 /pmc/articles/PMC3282700/ /pubmed/22363544 http://dx.doi.org/10.1371/journal.pone.0031050 Text en Akinsola et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Akinsola, Adebayo K.
Ota, Martin O. C.
Enwere, Godwin C.
Okoko, Brown J.
Zaman, Syed M. A.
Saaka, Mark
Nsekpong, Ekpedeme D.
Odutola, Aderonke A.
Greenwood, Brian M.
Cutts, Felicity T.
Adegbola, Richard A.
Pneumococcal Antibody Concentrations and Carriage of Pneumococci more than 3 Years after Infant Immunization with a Pneumococcal Conjugate Vaccine
title Pneumococcal Antibody Concentrations and Carriage of Pneumococci more than 3 Years after Infant Immunization with a Pneumococcal Conjugate Vaccine
title_full Pneumococcal Antibody Concentrations and Carriage of Pneumococci more than 3 Years after Infant Immunization with a Pneumococcal Conjugate Vaccine
title_fullStr Pneumococcal Antibody Concentrations and Carriage of Pneumococci more than 3 Years after Infant Immunization with a Pneumococcal Conjugate Vaccine
title_full_unstemmed Pneumococcal Antibody Concentrations and Carriage of Pneumococci more than 3 Years after Infant Immunization with a Pneumococcal Conjugate Vaccine
title_short Pneumococcal Antibody Concentrations and Carriage of Pneumococci more than 3 Years after Infant Immunization with a Pneumococcal Conjugate Vaccine
title_sort pneumococcal antibody concentrations and carriage of pneumococci more than 3 years after infant immunization with a pneumococcal conjugate vaccine
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3282700/
https://www.ncbi.nlm.nih.gov/pubmed/22363544
http://dx.doi.org/10.1371/journal.pone.0031050
work_keys_str_mv AT akinsolaadebayok pneumococcalantibodyconcentrationsandcarriageofpneumococcimorethan3yearsafterinfantimmunizationwithapneumococcalconjugatevaccine
AT otamartinoc pneumococcalantibodyconcentrationsandcarriageofpneumococcimorethan3yearsafterinfantimmunizationwithapneumococcalconjugatevaccine
AT enweregodwinc pneumococcalantibodyconcentrationsandcarriageofpneumococcimorethan3yearsafterinfantimmunizationwithapneumococcalconjugatevaccine
AT okokobrownj pneumococcalantibodyconcentrationsandcarriageofpneumococcimorethan3yearsafterinfantimmunizationwithapneumococcalconjugatevaccine
AT zamansyedma pneumococcalantibodyconcentrationsandcarriageofpneumococcimorethan3yearsafterinfantimmunizationwithapneumococcalconjugatevaccine
AT saakamark pneumococcalantibodyconcentrationsandcarriageofpneumococcimorethan3yearsafterinfantimmunizationwithapneumococcalconjugatevaccine
AT nsekpongekpedemed pneumococcalantibodyconcentrationsandcarriageofpneumococcimorethan3yearsafterinfantimmunizationwithapneumococcalconjugatevaccine
AT odutolaaderonkea pneumococcalantibodyconcentrationsandcarriageofpneumococcimorethan3yearsafterinfantimmunizationwithapneumococcalconjugatevaccine
AT greenwoodbrianm pneumococcalantibodyconcentrationsandcarriageofpneumococcimorethan3yearsafterinfantimmunizationwithapneumococcalconjugatevaccine
AT cuttsfelicityt pneumococcalantibodyconcentrationsandcarriageofpneumococcimorethan3yearsafterinfantimmunizationwithapneumococcalconjugatevaccine
AT adegbolaricharda pneumococcalantibodyconcentrationsandcarriageofpneumococcimorethan3yearsafterinfantimmunizationwithapneumococcalconjugatevaccine